啓明醫療-B:2023年度報告
Kai Ming Medical-B (02500.HK): Further updates on unauthorized loans and pledge deposits continue to be suspended
Gelonghui, April 16, 丨 Qiming Medical-B (02500.HK) issued an announcement. As of the date of this announcement, an unauthorized pledge deposit of RMB 100 million provided by Hangzhou Qiyi (a wholly-owned subsidiary of the company) to guarantee the Hangzhou Kuntai loan (due to expire on April 14, 2024) has been released from the relevant bank and further withdrawn by the company from the bank. Furthermore, as of the date of this announcement, Hangzhou Qiyi has received interest income of RMB 2,0506 million on these deposits. On the date of this announcement, the Group's previous pledges were made to guarantee the loan and on the date of the forensic investigation announcement
Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21%
Venus Medtech (Hangzhou) (HKG:2500) narrowed its loss attributable to owners of the parent to 720.9 million yuan in 2023, from 1.06 billion yuan in the year-ago period, according to a March 28 filing
Qiming Medical-B (02500) released annual results, gross profit of 389 million yuan, a year-on-year increase of 23.95%
Qiming Medical-B (02500) announced its annual results for the year ended December 31, 2023. The group...
VENUS MEDTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Express News | Huitianfu Fund: The suspended stock “Qiming Medical-B” is valued at HK$4.215 per share
VENUS MEDTECH-B: DATE OF BOARD MEETING AND CONTINUED SUSPENSION OF TRADING
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Express News | Shenzhen Stock Exchange: Changes to the list of Hong Kong Stock Exchange securities under the Shenzhen-Hong Kong Stock Connect
Qiming Medical-B (02500) after suspension of trading: facing internal control risks and consolidating the medium- to long-term intrinsic value growth base
The announcement revealed the corresponding progress of the five resumption guidelines proposed by the Hong Kong Stock Exchange after the suspension of trading last year. However, Qiming Medical has adopted a positive attitude and proposed practical solutions to internal control risk issues that have arisen.
Opinion | Hang Seng Index quarterly inspection results announced, which companies are expected to become the Hong Kong Stock Exchange Index?
After the market on February 16, 2024, Hang Seng Indices announced the results of its regular semi-annual index adjustments (the review ends on December 31, 2023, and is generally announced within 8 weeks after the inspection date). The scope of this adjustment covers the main flagship indices of Hong Kong stocks, such as the Hang Seng, the State-owned Enterprises Index, and the Hang Seng Technology Index; in addition, the Hang Seng Composite Index, which directly determines the scope of investment in Hong Kong Stock Connect, has also been adjusted.
Kai Ming Medical-B (02500) received additional guidance from the Exchange to resume trading and continued to be suspended
According to Zhitong Financial App News, Qiming Medical-B (02500) announced that the company received a letter from the Stock Exchange on February 9, 2024. According to this, the Stock Exchange issued additional guidance on resuming trading to the company after the death of Mr. Lau Yun-yi: re-complying with the requirements of section 3.10 (1), section 3.10A, section 3.21 and section 3.27A of the listing rules relating to the composition and chairman of the board committee (if applicable). Trading of the company's shares continues to be suspended.
Qiming Medical-B (02500): Independent non-executive director Liu Yunyi passed away
Qiming Medical-B (02500) issued an announcement, independent non-executive director, chairman of the board nomination committee, remuneration and examination...
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Venus Medtech Names Former 3SBio Finance Chief as CFO
Venus Medtech (Hangzhou) (HKG:2500) appointed Fei Wang as its chief financial officer effective today, Thursday, a same-day filing by the heart valve medical device manufacturer said. Wang was previou
Qiming Medical-B (02500.HK): Wang Fei appointed as Chief Financial Officer
Gelonghui January 4 | Qiming Medical-B (02500.HK) issued an announcement. Wang Fei has been appointed as Chief Financial Officer with effect from January 4, 2024. Trading of the Company's shares has been suspended on the Stock Exchange since 9:00 a.m. on November 23, 2023, and will continue to be suspended until further notice.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Venus Medtech Gets Trading Resumption Guidance
The Hong Kong Stock Exchange required Venus Medtech (Hangzhou) (HKG:2500) to conduct an investigation and independent review as part of its guidance to resume trading. The forensic investigation into
Kai Ming Medical-B (02500.HK) receives guidance on the resumption of trading from the Stock Exchange
Gelonghui, December 27 | Qiming Medical-B (02500.HK) announced that on December 20, 2023, the company received a letter from the Stock Exchange setting out the guidelines for resuming trading of the company's shares (collectively referred to as the resumption guidelines). According to the resumption guidelines, the company shall: (a) conduct a special audit and conduct an appropriate supervisory investigation with respect to (a) the provision of loans to Mr. Zi and Mr. Tsang and (b) other financial flows between the Group and Mr. Zi, Mr. Tsang and/or any entity owned or controlled separately or jointly by them, as may be discovered during the special review, and publish the findings and take appropriate remedial action; (b)
No Data